PHRM-01. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE DNA HYPOMETHYLATING AGENT, GUADECITABINE (SGI-110), FOLLOWING SUBCUTANEOUS ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL

BACKGROUND: Guadecitabine, a potent hypomethylating agent currently being studied in clinical trials, is a dinucleotide that is resistant to degradation by cytidine deaminase resulting in an extended release of the active metabolite decitabine following subcutaneous (SC) administration. The CSF expo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Lester McCully, Cynthia M, Odabs, Arman, Cruz, Rafael, Peer, Cody, Figg, William D, Glod, John W, Warren, Katherine E
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012492/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.579
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares